Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Revenue | $7.00M | $13.0M |
| Revenue growth | — | 85.7% |
| Operating income | -$70.0M | -$81.1M |
| Operating margin | -1000.2% | -623.6% |
| Net income | -$66.8M | -$68.9M |
| Net margin | -954.4% | -529.8% |
| EPS (diluted) | -$45.29 | -$11.22 |
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Operating cash flow | -$58.2M | -$76.4M |
| Capital expenditures | $88.0K | $235K |
| Free cash flow | -$58.3M | -$76.7M |
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Cash & equivalents | $16.3M | $44.1M |
| Total assets | $76.1M | $225M |
| Total liabilities | $28.5M | $19.4M |
| Shareholders' equity | -$144M | $206M |
| Retained earnings | -$152M | -$221M |
| Shares (wtd avg diluted) | 1.51M | 6.14M |
Every figure is extracted from Evommune, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.